Ratings by Cantor Fitzgerald (Olivia Brayer Saunders)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/20/2026 | Ensysce Biosciences Inc. | ENSC | New Coverage | Overweight (N/A) |
0.50 (0.42) |
-16% | Details | |
| 9/24/2026 | Mesoblast Limited | MESO | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/10/2026 | Tenax Therapeutics | TENX | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/31/2026 | Braveheart Bio | BRVE | New Coverage | Overweight (N/A) |
27.44 (21.51) |
-21.61% | Details | |
| 8/18/2026 | Quince Therapeutics Inc. | QNCX | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/21/2026 | Connect Biopharma Holdings Ltd | CNTB | New Coverage | Overweight (N/A) |
2.31 (0.80) |
-65.37% | Details |
